Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Thoracic Stent Graft Improves Aortic Aneurysm Repair

By HospiMedica staff writers
Posted on 18 Jun 2008
A thoracic stent graft system has been developed for minimally invasive treatment of aneurysms of the descending thoracic aorta. More...


The Talent Thoracic Stent Graft System is a modular, self-expanding prosthesis designed for endoluminal exclusion of aortic aneurysms. It consists of a series of serpentine nickel-titanium (nitinol) stents embedded into woven Dacron fabric; the stents are spaced discontinuously along a full-length nitinol spine. The delivery system is a coaxial sheath with pusher rod and a compliant polyurethane balloon used to maximize attachment to the vascular wall and ensure full expansion throughout the length of the device. The Talent is available in a wide range of diameters, from 22 to 46 mm. This offers physicians multiple options to customize devices for their patients' needs and to treat a wider range of anatomies than with the other available endografts, making thoracic endovascular aortic repair (TEVAR) accessible to an additional 25% of patients. Salient features of the Talent device include the proximal bare-spring (uncovered nitinol stent) and custom manufacturing to fit a wide range of aorto-iliac sizes and configurations, as determined preoperatively by computed-tomographic (CT) imaging and angiography. The Talent Thoracic Stent Graft System is a product of Medtronics (Minneapolis, MN, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

"There are still many patients undiagnosed and in need of treatment for thoracic aortic disease,” said Ronald Fairman, M.D., a professor of surgery and chief of vascular surgery at the University of Pennsylvania Hospital (Philadelphia, USA). "FDA approval of the Talent Thoracic Stent Graft is an important development in physicians' abilities to treat this life-threatening condition. In my own experience, this device offers a superior alternative to open surgery and will allow physicians to perform minimally-invasive thoracic aortic aneurysm repair for a broader population of patients.”

Thoracic aneurysms most often occur in the descending thoracic aorta. Others may appear in the ascending aorta or the aortic arch. The most common cause of a thoracic aortic aneurysm is atherosclerosis. Other risk factors include various connective tissue disorders such as Marfan syndrome, previous dissection of the aorta, high blood pressure, trauma such as falls or motor vehicle accidents, and syphilis. For patients with aneurysms of the ascending aorta or aortic arch, surgery to replace the aorta is recommended if the aneurysm is larger than 5-6 cm. There are two options for patients with aneurysms of the descending thoracic aorta; if the aneurysm is larger than six cm, major surgery is done to replace the aorta with a fabric substitute. Endovascular stenting is a less invasive option.


Related Links:
Medtronics

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.